Sulodexide up-regulates glutathione S-transferase P1 by enhancing Nrf2 expression and translocation in human umbilical vein endothelial cells injured by oxygen glucose deprivation.
Nrf2
endothelium
glutathione S-transferase P1
ischemia
sulodexide
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
12
2018
accepted:
06
01
2019
entrez:
17
6
2020
pubmed:
11
2
2019
medline:
11
2
2019
Statut:
epublish
Résumé
Sulodexide (SDX) is used for the treatment of many vascular disorders due to its anticoagulant, anti-inflammatory and anti-atherosclerotic properties. However, the detailed molecular mechanism of its endothelioprotective action is still not completely understood. There is increasing evidence suggesting that antioxidant enzymes play an important role in anti-ischemic properties of SDX. We postulate that up-regulation of glutathione-S-transferase P1 (GSTP1) mediated by the transcription factor Nrf2 could be associated with the antioxidant effect of SDX on vascular endothelial cells. In the present study, we investigated whether SDX affects GSTP1 and Nrf2 in oxygen glucose deprivation (OGD) treated human umbilical vein endothelial cells (HUVECs). The cells treated with/without SDX (0.5 LRU/ml) were subjected to OGD for 1-6 h. To study the influence of SDX on the Nrf2 nucleus accumulation, the cells were incubated with 0.5 LRU/ml SDX in OGD for 1 h. We found that after short-term OGD (1-3 h), the drug increased the expression of both GSTP1 and Nrf2 mRNA/protein in HUVECs ( SDX induces a rapid onset of the antioxidant response by up-regulating the expression of GSTP1 and Nrf2 in endothelial cells subjected to
Identifiants
pubmed: 32542099
doi: 10.5114/aoms.2019.82818
pii: 35794
pmc: PMC7286338
doi:
Types de publication
Journal Article
Langues
eng
Pagination
957-963Informations de copyright
Copyright © 2019 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Curr Vasc Pharmacol. 2014 Jan;12(1):173-85
pubmed: 24279420
Cell Physiol Biochem. 2016;40(5):1005-1012
pubmed: 27941341
J Endocrinol. 2015 Jun;225(3):R83-99
pubmed: 25918130
J Vasc Res. 2015;52(1):53-61
pubmed: 26045187
Biochem Biophys Res Commun. 2013 Jul 19;437(1):134-9
pubmed: 23806685
Eur J Pharmacol. 2007 Mar 8;558(1-3):167-71
pubmed: 17258198
CNS Neurosci Ther. 2016 Oct;22(10):836-44
pubmed: 27324700
Annu Rev Pharmacol Toxicol. 2003;43:233-60
pubmed: 12359864
Mol Med. 2001 Feb;7(2):135-45
pubmed: 11471548
J Biol Chem. 2010 Aug 20;285(34):26135-48
pubmed: 20538586
Circ Res. 2000 Nov 10;87(10):840-4
pubmed: 11073878
Neurobiol Dis. 2016 May;89:136-46
pubmed: 26850917
Biochem Pharmacol. 2013 Mar 15;85(6):705-17
pubmed: 23219527
Adv Cancer Res. 2014;122:143-75
pubmed: 24974181
J Pharmacol Exp Ther. 2001 Jan;296(1):1-6
pubmed: 11123355
Mol Pharmacol. 2007 Oct;72(4):1074-81
pubmed: 17652445
Molecules. 2016 Aug 09;21(8):
pubmed: 27517893
Drug Des Devel Ther. 2013 Dec 24;8:49-65
pubmed: 24391440
Am J Transl Res. 2016 Feb 15;8(2):765-77
pubmed: 27158368
Anal Biochem. 1987 Apr;162(1):156-9
pubmed: 2440339
Mol Cell Biol. 2003 Nov;23(22):8137-51
pubmed: 14585973
Molecules. 2011 Nov 03;16(11):9234-44
pubmed: 22051934
J Pediatr Surg. 2002 Nov;37(11):1543-8
pubmed: 12407536
Arch Med Sci. 2018 Jun;14(4):735-744
pubmed: 30002689
J Biol Chem. 2017 Aug 25;292(34):14108-14121
pubmed: 28684421
Trends Cardiovasc Med. 2014 May;24(4):165-9
pubmed: 24373981
Circ Res. 2015 Aug 14;117(5):437-49
pubmed: 26169370
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
PLoS One. 2015 Jun 01;10(6):e0128455
pubmed: 26029932
J Agric Food Chem. 2012 Jul 4;60(26):6537-45
pubmed: 22676582
Exp Clin Cardiol. 2011 Fall;16(3):92-6
pubmed: 22065940